On September 4, Zhifei Biotech reported on WeChat. Recently, the launch ceremony for the Liraglutide injection independently developed by its holding subsidiary Chongqing Chen'an Biotech was successfully held, marking the official entry of this product into the market, laying the foundation for subsequent large-scale supply and market expansion. According to reports, Liraglutide Injection Dashuchen® is a GLP-1 receptor agonist, suitable for controlling blood sugar in adult type 2 diabetics and reducing the risk of major cardiovascular adverse events in adult patients with type 2 diabetes with cardiovascular disease.

On September 4, Zhifei Biotech reported on WeChat. Recently, the launch ceremony for the Liraglutide injection independently developed by its holding subsidiary Chongqing Chen'an Biotech was successfully held, marking the official entry of this product into the market, laying the foundation for subsequent large-scale supply and market expansion. According to reports, Liraglutide Injection Dashuchen® is a GLP-1 receptor agonist, suitable for controlling blood sugar in adult type 2 diabetics and reducing the risk of major cardiovascular adverse events in adult patients with type 2 diabetes with cardiovascular disease.